Safety and Efficacy of the RTS,S/AS01E Candidate Malaria
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Digital Library of the Tanzania Health Community Articles Safety and effi cacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial Kwaku Poku Asante, Salim Abdulla, Selidji Agnandji, John Lyimo, Johan Vekemans, Solange Soulanoudjingar, Ruth Owusu, Mwanajaa Shomari, Amanda Leach, Erik Jongert, Nahya Salim, Jose F Fernandes, David Dosoo, Maria Chikawe, Saadou Issifou, Kingsley Osei-Kwakye, Marc Lievens, Maria Paricek, Tina Möller, Stephen Apanga, Grace Mwangoka, Marie-Claude Dubois, Tigani Madi, Evans Kwara, Rose Minja, Aurore B Hounkpatin, Owusu Boahen, Kingsley Kayan, George Adjei, Daniel Chandramohan, Terrell Carter, Preeti Vansadia, Marla Sillman, Barbara Savarese, Christian Loucq, Didier Lapierre, Brian Greenwood, Joe Cohen, Peter Kremsner, Seth Owusu-Agyei, Marcel Tanner, Bertrand Lell Summary Background The RTS,S/AS01E candidate malaria vaccine is being developed for immunisation of infants in Africa Lancet Infect Dis 2011; through the expanded programme on immunisation (EPI). 8 month follow-up data have been reported for safety and 11: 741–49 Published Online immunogenicity of RTS,S/AS01E when integrated into the EPI. We report extended follow-up to 19 months, including effi cacy results. July 21, 2011 DOI:10.1016/S1473- 3099(11)70100-1 Methods We did a randomised, open-label, phase 2 trial of safety and effi cacy of the RTS,S/AS01E candidate malaria This online publication vaccine given with EPI vaccines between April 30, 2007, and Oct 7, 2009, in Ghana, Tanzania, and Gabon.
[Show full text]